Resistance of Chlamydia trachomatis to antibiotics

Abstract

Some aspects of Chlamydia trachomatis resistance to antihiotics are reviewed: possihle mechanisms, clinical significance of in vitro resistance, and the role of antihiotics in induction of persistence.

Keywords

chlamydia trachomatis / antibiotics / chlamydia / chlamydial infection therapy

References

[1] Adams D. Е., Shekhtmann Е. М., Zechiedrich Е. I., Schmid М. В., Cozzarelli N. R. The role of topoisomerase IV in pardoning bacterial replicons and structure of catenated intermediates in DNA replication //Cell — Vol. 71. —P. 277-288.

[2] Allaire A. D., Huddleston J. F., Graves W. L. Initial and repeat screening for Chlamydia trachomatis during pregnancy // Infect. Dis. Obstet. Gynecol. — 1998. — Vol. 6. — P. 116-122.

[3] Beatty W. L., Belanger T. A., Desai A. A., Morrison R. P., Byrne G. L. Tryptophan depletion as a mechanism of gamma interferon - mediated chlamydial persistence // Infect. Immun. — 1994. — Vol. 62. — P. 3705-3711.

[4] Beatty W. L., Byrne G. L., Morrison R. P. Morphological and antigenic characterization of interferon-r mediated persistent Chlamydia trachomatis infection in vitro // Proc. Natl. Acad. Sci. USA — 1993. - Vol. 90. - P. 3998-4002.

[5] Beatty W. L., Morrison R. P., Byrne G. L. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis // Microbiol. Rev. — 1994. — Vol. 58. — P. 689-699.

[6] Beatty W. L., Morrison R. P., Byrne G. L. Reactivation of persistent Chlamydia trachomatis in cell culture // Infect. Immun. — 1995. — Vol. 63. —P. 199-205.

[7] Belland R. J., Morrison S. G., Ison C., Huang W. B. Neisseria gonorrhoeae acquires mutations in analogous regions of gуrA and parC in fluoroquinolone-resistant isolates // Mol. Microbiol. — 1994. — Vol. 14. — P. 371-380.

[8] Blythe M. J., Katz В. P., Batteiger В. E., Ganser J. A., Jones A. B. Recurrent genitourinary chlamydial infections in sexually active female adolescents // J. Pediatr. — 1992. — Vol. 121. - P. 487-493.

[9] Bolhuis H., Van Veen H. W., Poolman B., Driessen A. J., Konings W. N. Mechanisms of multidrug transporters // FEMS Microbiol. Rev. — 1997. — Vol. 21. — P. 55-84.

[10] Bragina E. Y., Gomberg M. A., Dmitriev G. A. Electron microscopic evidence of persistent chlamydial infection following treatment // J.Eur. Acad. Dermatol. Venerol. — 2001. - Vol. 15. - P. 405-409.

[11] Byrne G. L. Chlamydiae treatment failure: a persistent problem?// J. Eur. Acad. Dermatol. Venerol. - 2001. - Vol. 15. -P. 381.

[12] Campbell L. A., Patton D. L., Moore D. E., Cappuccino A. L., Mueller B. A., Wang S.-P. Detection of Chlamydia trachomatis deoxyribonucleic acid in women with tubal infertility // Fertil. Steril. — 1993. - Vol. 59. - P. 45-50.

[13] Chittum H. S., Champney W. S. Erythromycin inhibits the assembly of the large ribosomal subunit in growing Echerichia coli cells // Curr. Microbiol. - 1995. - Vol. 30. -P. 273-279.

[14] Chopra I., Hawkey P. M., Hinton M. Tetracyclines, molecular and clinical aspects // J. Antimicrob. Chemother. — 1992. - Vol. 29. —P. 247-277.

[15] Dean D., Suchland R. J., Stamm W. E. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping // J. Infect. Dis. - 2000. - Vol. 182. - P. 909-916.

[16] Dessus-Babus S., Bebear С. M., Charron A., Bebear C., Barbeyrac B. Sequencing of gyrase and topoisomerase IV quinolone- resistance-determining regions of Chlamydia trachomatis and characterization of quinolone- resistant mutants obtained in vitro // Antimicrob. Agents Chemother. — 1998. - Vol. 42. - P. 2474-2478.

[17] Dreses-Werringloer U., Padubrin I., Jurgens-Saathoff B., Hudson A. P., Zeidler H., Kohler R. Persistence of Chlamydia trachomatis induced by ciprofloxacin and ofloxacin in vitro // Antimicrob. Agents Chemother. — 2000. - Vol. 44. - P. 3288-3297.

[18] Dreses-Werringloer U., Padubrin I., Zeidler H., Kohler R. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro // Antimicrob. Agents Chemother. — 2001. — Vol. 45. —P. 3001-3008.

[19] Hackstadt T., Scidmore-Carlson M., Shaw E., Fischer E. The Chlamydia trachomatis IncA protein is required for homotypic vesicle fusion // Cell. Microbiol. — 1999. — Vol. 1. —P. 119-130.

[20] Hooper D. C. Mechanisms of action and resistance to older and newer fluoroquinolones // Clin. Infect. Dis. — 2000. — Vol. 31. — Suppl. 2. - P. S24-28.

[21] Hooper D. C. Mechanisms of fluoroquinolone resistance // Drug Resistance Updates. — 1999. — Vol. 2. - P. 38-55.

[22] Hooton T. M., Rogers M. E, Medina T. G., Kuwamura L. E., Ewers C., Roberts P. L., Stamm W. E. Ciprofloxacin compared with doxycycline for nongonococcal urethritis // JAMA — 1990. —Vol. 264. - P. 1418-1421.

[23] Iliffe-Lee E. R., McClarty G. Glucose metabolism in Chlamydia trachomatis: ‘energy parasite’ hypothesis revisited // Mol. Microbiol. - 1999. - Vol. 33. -P. 177-187.

[24] Jenkins G., Cundliffe E. Cloning and characterization of two genes from Streptomyces lividans that confer inducible resistance to lincomycin and macrolide antibiotics// Gene —1991. — Vol. 108. - P. 55-62.

[25] Jones R. B., Van der Pol B., Martin D. H., Shepard M. K. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics // J. Infect. Dis. - 1990. - Vol. 162. - P. 1309-1315.

[26] Kaatz G. W., Seo S. M., Ruble C. A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus // Antimicrob. Agents Chemother. —1993. — Vol. 37. — 1086-1094.

[27] Kanematsu E., Degushi T., Yashida M. Alterations in the GyrA subunit of the DNA gyrase and ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis // Antimicrob. Agents Chemother. — 1998. - Vol. 42. - P. 433-435.

[28] Kjar H. O., Dimcevski G., Hoff G., Olesen F., Ostergaard L. Recurrence of urogenital Chlamydia trachomatis infection evaluated by mailed samples obtained at home: 24 weeks’ prospective follow upstudy //Sex. Transm. Inf. —2000. - Vol. 76. - P. 169-172.

[29] Kumagai Y., Kato J. I., Hoshino K., Akasaka T., Sato K., Ikeda H. Quinolone-resistant mutants of Esherichia coli DNA topoisomerase IV parC gene // Antimicrob. Agents Chemother.—1996- Vol. 40. - P. 710-714.

[30] Lefevre J. C., Lepargneur J. P., Guion D., Bei S. Tetracyclineresistant Chlamydia trachomatis in Toulouse, France // Pathol. Biol. —1997 - Vol. 45. - P. 376-378.

[31] Miller J. M. Recurrent chlamydial colonization during pregnancy // Am. J. Perinatol. — 1998. — Vol. 15. - P. 307-309.

[32] Moore R. A., Beckhold B., Wong S., Kureishi A., Bryan L. E. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori // Antimicrob. Agents Chemother. — 1995. — Vol. 39. - P. 107-111.

[33] Mourad A., Sweet R. L., Sugg N., Schachter J. Relative resistance to erithromycin in Chlamydia trachomatis // Antimicrob. Agents Chemother. — 1980. — Vol. 18. — P. 696-698.

[34] Munday P. I., Thomas B. J., Gilroy С. B., Gilchrist C., Taylor- Robinson D. Infrequent detection of Chlamydia trachomatis in a longitudinal study of women with treated cervical infection // Genitourin. Med. — 1995. — Vol. 71.— P. 24-26.

[35] Nakano M., Degushi T., Kawamura T., Yashida M. Mutation in the дуrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa //Antimicrob. Agents Chemother. — 1998. — Vol. 41. — P. 2289-2291.

[36] Nicaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux // Science - Vol. 264. - P. 382-388.

[37] Paulsen I. T., Broun M. H., Skurray R. A. Proton-dependent multidrug efflux sistems // Microbiol. Rev. — 1996. - Vol. 60. - P. 575-608.

[38] Ridgway G. L. Treatment of chlamydial genital infection // J. Antimicrob. Chemother. — 1997. — Vol. 40. - P. 311-314.

[39] Ross J. I., Eady E. A., Cove J. H., Cunliffe W. J., Baumberg S., Wootton J. C. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP- binding transport super-gene family/ / Mol. Microbiol. —1990. — Vol. 4. —P. 1207-1214.

[40] Shaw E. I., Dooley C. A., Fisher E. R., Scidmore M. A., Fields K. A., Hackstadt T. Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle // Mol. Microbiol. — 2000. - Vol. 37. -P. 913-925.

[41] 41 .Somani J., Bhullar V. B., Workowski K. A., Farshy С. E., Black С. M. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure // J. Infect. Dis. - 2000. - Vol. 181. - P. 1421-1427.

[42] Tjaden J., Winkler H. H., Schwoppe C., Van der Laan M., Mohlmann T., Neuhaus H. E. Two nucleotide transport proteins in Chlamydia trachomatis, one for net nucleoside triphosphate uptake and the other for transport of energy//J. Bacteriology. — 1999. — Vol. 181. — P. 1196-1202.

[43] Van der Willigen A. H., Polak- Vogelzang A. A., Habbema L., Waagenvoort J. H. T. Clinical efficacy of ciprofloxacin versus doxycycline in the treatment of nongonococcal urethritis in males // Eur. J. Clin. Microbiol. Infect. Dis. — 1988. - Vol. 7. - P. 658-661.

[44] Van Ooij С., Homola E., Kincaid E., Engel J. Fusion of Chlamydia trachomatis-containing inclusions is inhibited at low temperatures and requires bacterial protein synthesis // Infect. Immun. — 1998. — Vol. 66. — P. 5364-5371.

[45] Wang J. C. DNA topoisomerases// Annu. Rev. Biochem. — 1996. — Vol. 65. - P. 635-692.

[46] Weisblum B. Erythromycin resistance by ribosome modification // Antimicrob. Agents Chemother. — 1995. - Vol. 39. - P. 577-585.

[47] Yoshida H., Bogaki M., Nakamura M., Nakamura S. Quinolone-resistance-determining region in the DNA gyrase gyrA gene of Esherichia coli // Antimicrob. Agents Chemother. — 1990. —Vol. 34. - P. 1271-1272.

RIGHTS & PERMISSIONS

Eсо-Vector